"Company","Parent Company","Penalty Amount","Subtraction From Penalty","Penalty Amount Adjusted For Eliminating Multiple Counting","Penalty Year","Penalty Date","Offense Group","Primary Offense","Secondary Offense","Description","Level of Government","Action Type","Agency","Civil/Criminal","Prosecution Agreement","Court","Case ID","Private Litigation Case Title","Lawsuit Resolution","Facility State","City","Address","Zip","NAICS Code","NAICS Translation","HQ Country of Parent","HQ State of Parent","Ownership Structure","Parent Company Stock Ticker","Major Industry of Parent","Specific Industry of Parent","Info Source","Notes"
"Alpharma Inc.","Pfizer","$42,500,000","$0","$42,500,000","2010","20100316","government-contracting-related offenses","False Claims Act and related","kickbacks and bribery","Alpharma Inc. agreed to pay $42.5 million to resolve False Claims Act allegations in connection with the marketing of the morphine-based drug Kadian. The settlement resolved allegations that between January 1, 2000 and December 29, 2008 Alpharma paid health care providers to induce them to promote or prescribe Kadian, and made misrepresentations about the safety and efficacy of the drug. ","federal","agency action","Justice Department Civil Division","civil","","","","","","","","","","","","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","https://www.justice.gov/opa/pr/alpharma-pay-425-million-resolve-false-claims-act-allegations-connection-promotion-drug",""
"Alpharma, Inc.","Pfizer","$2,500,000","$0","$2,500,000","2004","20040812","competition-related offenses","price-fixing or anti-competitive practices","consumer protection violation","Generic drug manufacturers Alpharma Inc. and Perrigo Company agreed to give up a total of $6.25 million in illegal profits to settle Federal Trade Commission allegations that their agreement to limit competition for over-the-counter store-brand children's liquid ibuprofen drove up prices and violated federal law.","federal","agency action","Federal Trade Commission","civil","","","","","","","","","","","","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","https://www.ftc.gov/news-events/press-releases/2004/08/generic-drug-marketers-settle-ftc-charges",""
"Hospira Inc.","Pfizer","$400,000","$0","$400,000","2015","20151013","employment-related offenses","employment discrimination","","Hospira Inc., a government contractor, discriminated against women in violation of Executive Order 11246 when it denied jobs to 145 female applicants for pharmacy attendant positions at its McPherson, Kansas, facility, the Office of Federal Contract Compliance Programs found. ","federal","agency action","Office of Federal Contract Compliance Programs","civil","","","","","","Kansas","McPherson","","","","","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","https://www.dol.gov/opa/media/press/ofccp/OFCCP20152014.htm",""
"King Pharmaceuticals","Pfizer","$124,000,000","$0","$124,000,000","2005","20051101","government-contracting-related offenses","False Claims Act and related","","King Pharmaceuticals agreed to pay $124 million plus interest to resolve allegations that it underpaid rebates owed under the Medicaid program and overcharged various federal and state governmental entities for its drug products.","federal","agency action","Justice Department Civil Division","civil","","","","","","","","","","","","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","https://www.justice.gov/archive/opa/pr/2005/November/05_civ_581.html",""
"King Pharmaceuticals LLC","Pfizer","$2,200,000","$0","$2,200,000","2013","20130628","environment-related offenses","environmental violation","","King Pharmaceuticals LLC (King) will pay $2.2 million and take measures to comply with the Clean Air Act to resolve alleged violations of the Clean Air Act (CAA) at its pharmaceutical manufacturing facility located in Bristol, Tenn., announced the Department of Justice, the U.S. Environmental Protection Agency (EPA), and the Tennessee Department of Environment and Conservation (TDEC).","federal","agency action","Environmental Protection Agency referral to the Justice Department","civil","","","","","","Tennessee","Bristol","","","","","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","http://www.justice.gov/opa/pr/united-states-and-tennessee-reach-agreement-king-pharmaceuticals-llc-resolve-allegations",""
"Pfizer Corporation","Pfizer","$49,000,000","$0","$49,000,000","2002","20021028","government-contracting-related offenses","False Claims Act and related","","Pfizer Corporation and its subsidiaries, Warner-Lambert and Parke-Davis, agreed to pay $49 million to settle allegations that they violated the False Claims Act by failing to fully pay the rebates owed to state and federal governments for the cholesterol-lowering drug Lipitor.","federal","agency action","Justice Department Civil Division","civil","","","","","","","","","","","","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","https://www.justice.gov/archive/opa/pr/2002/October/02_civ_622.htm",""
"Pfizer Inc.","Pfizer","$2,300,000,000","$0","$2,300,000,000","2009","20090902","healthcare-related offenses","off-label or unapproved promotion of medical products","","American pharmaceutical giant Pfizer Inc. and its subsidiary Pharmacia & Upjohn Company Inc. agreed to pay $2.3 billion to resolve criminal and civil liability arising from the illegal promotion of certain pharmaceutical products. Pfizer was required to pay a criminal fine of $1.195 billion and Pharmacia & Upjohn was required to forfeit $105 million, for a total criminal resolution of $1.3 billion. The other $1 billion represented a civil False Claims Act penalty.","federal","agency action","Justice Department Civil Division","civil and criminal","","","","","","","","","","","","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","https://www.justice.gov/opa/pr/justice-department-announces-largest-health-care-fraud-settlement-its-history",""
"Pfizer Inc.","Pfizer","$784,600,000","$0","$784,600,000","2016","20160427","government-contracting-related offenses","False Claims Act and related","","The Department of Justice announced that pharmaceutical companies Wyeth and Pfizer Inc. agreed to pay $784.6 million to resolve allegations that Wyeth knowingly reported to the government false and fraudulent prices on two of its proton pump inhibitor drugs, Protonix Oral and Protonix IV.  Pfizer acquired Wyeth in 2009, approximately three years after Wyeth had ended the conduct that gave rise to the settlement.","federal","agency action","Justice Department Civil Division","civil","","","","","","","","","","","","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","https://www.justice.gov/opa/pr/wyeth-and-pfizer-agree-pay-7846-million-resolve-lawsuit-alleging-wyeth-underpaid-drug-rebates",""
"Pfizer Inc.","Pfizer","$55,000,000","$0","$55,000,000","2012","20121212","safety-related offenses","drug or medical equipment safety violation","","Pfizer Inc. agreed to pay $55 million plus interest to resolve allegations that Wyeth LLC illegally introduced and caused the introduction into interstate commerce of a misbranded drug, Protonix, between February 2000 and June 2001.","federal","agency action","Food and Drug Administration referral to the Justice Department","civil","","","","","","","","","","","","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","http://www.justice.gov/opa/pr/pfizer-agrees-pay-55-million-illegally-promoting-protonix-label-use",""
"Pfizer Inc.","Pfizer","$26,339,944","$0","$26,339,944","2012","20120807","competition-related offenses","Foreign Corrupt Practices Act","","","federal","agency action","Securities and Exchange Commission","civil","","","","","","","","","","","","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","https://www.sec.gov/News/PressRelease/Detail/PressRelease/1365171483696",""
"Pfizer Inc.","Pfizer","$14,500,000","$0","$14,500,000","2011","20111021","healthcare-related offenses","off-label or unapproved promotion of medical products","","American pharmaceutical company Pfizer Inc. agreed to pay $14.5 million to resolve False Claims Act allegations related to its marketing of the drug Detrol. The settlement resolved the last of a group of 10 qui tam, or whistleblower, suits that were filed in the District of Massachusetts and two other districts, beginning in 2003. The other nine suits were settled or dismissed in 2009 as part of the government's global resolution with Pfizer, under which the company agreed to pay $2.3 billion dollars to resolve civil claims and criminal charges regarding multiple drugs.","federal","agency action","Food and Drug Administration referral to the Justice Department","civil","","","","","","","","","","","","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","http://www.justice.gov/opa/pr/pfizer-pay-145-million-illegal-marketing-drug-detrol",""
"Pfizer Inc.","Pfizer","$975,000","$0","$975,000","2008","20080623","environment-related offenses","environmental violation","","Pfizer Inc. agreed to pay a $975,000 civil penalty to resolve alleged violations of the Clean Air Act at its former manufacturing plant in Groton, Conn.","federal","agency action","Justice Department Environment and Natural Resources Division","civil","","","","","","Connecticut","Groton","","","","","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","https://www.justice.gov/archive/opa/pr/2008/June/08-enrd-555.html",""
"Pfizer Inc.","Pfizer","$11,250","$0","$11,250","2002","20020529","safety-related offenses","railroad safety violation","","","federal","agency action","Federal Railroad Administration","civil","","","","","","","","","","","","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","Taken from the Federal Railroad Administration's FY2002 safety penalty report obtained through a Freedom of Information Act request. A copy is available upon request. ",""
"Pfizer Pharmaceuticals LLC","Pfizer","$728,000","$0","$728,000","2014","20140512","environment-related offenses","environmental violation","","The U. S. Environmental Protection Agency announced that it has settled a case with Pfizer Pharmaceuticals LLC for violations of the Clean Air Act at the company's pharmaceutical manufacturing plant, in Barceloneta, Puerto Rico. Pfizer did not have the proper air pollution controls to prevent leaks of methylene chloride gas used in the manufacturing process. In addition to coming into compliance with the leak detection requirements, Pfizer has agreed to spend $410,000 to expand the municipal recycling program in Barceloneta. The company will also pay a civil penalty of $318,000.","federal","agency action","Environmental Protection Agency","civil","","","","","","Puerto Rico","Barceloneta","","","","","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","https://archive.epa.gov/epapages/newsroom_archive/newsreleases/e39379c592136f4085257cd60061d087.html",""
"Pfizer H.C.P. Corporation","Pfizer","$15,000,000","$0","$15,000,000","2012","20120807","competition-related offenses","Foreign Corrupt Practices Act","","Pfizer H.C.P. Corporation, an indirect wholly owned subsidiary of Pfizer Inc., agreed to pay a $15 million penalty to resolve an investigation of Foreign Corrupt Practices Act violations.","federal","agency action","Justice Department Criminal Division","criminal","deferred prosecution agreement","","","","","","","","","","","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","https://www.justice.gov/opa/pr/pfizer-hcp-corp-agrees-pay-15-million-penalty-resolve-foreign-bribery-investigation",""
"Warner-Lambert","Pfizer","$430,000,000","$0","$430,000,000","2004","20040513","healthcare-related offenses","off-label or unapproved promotion of medical products","kickbacks and bribery","Warner-Lambert agreed to plead guilty and pay more than $430 million to resolve criminal charges and civil liabilities in connection with its Parke-Davis division's allegedly  illegal and fraudulent promotion of unapproved uses for one of its Neurontin anti-seizure drug.","federal","agency action","Justice Department Civil Division","civil and criminal","","","","","","","","","","","","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","https://www.justice.gov/archive/opa/pr/2004/May/04_civ_322.htm",""
"PFIZER, INC.","Pfizer","$7,155","$0","$7,155","2009","20090417","safety-related offenses","workplace safety or health violation","","","federal","agency action","Occupational Safety & Health Administration","civil","","","","","","Connecticut","GROTON","GROTON/NEW LONDON LABS, EASTERN POINT ROAD","06340","541710","541710: Research and Development in the Physical, Engineering, and Life Sciences","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","Extracted from a download of OSHA's Enforcment Data downloaded on 3/02/2022, available at https://enforcedata.dol.gov/views/data_catalogs.php",""
"HOSPIRA","Pfizer","$6,750","$0","$6,750","2006","20060410","safety-related offenses","workplace safety or health violation","","","federal","agency action","Occupational Safety & Health Administration","civil","","","","","","Texas","AUSTIN","3900 HOWARD LANE","78728","325412","325412: Pharmaceutical Preparation Manufacturing","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","Extracted from a download of OSHA's Enforcment Data downloaded on 3/02/2022, available at https://enforcedata.dol.gov/views/data_catalogs.php",""
"HOSPIRA, INC.","Pfizer","$132,300","$0","$132,300","2004","20040701","safety-related offenses","workplace safety or health violation","","","federal","agency action","Occupational Safety & Health Administration","civil","","","","","","Illinois","NORTH CHICAGO","1401 SHERIDAN ROAD, M3B BUILDING","60064","325412","325412: Pharmaceutical Preparation Manufacturing","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","Extracted from a download of OSHA's Enforcment Data downloaded on 3/02/2022, available at https://enforcedata.dol.gov/views/data_catalogs.php",""
"KING PHARMACEUTICALS","Pfizer","$7,200","$0","$7,200","2001","20010124","safety-related offenses","workplace safety or health violation","","","federal","agency action","Occupational Safety & Health Administration","civil","","","","","","Tennessee","BRISTOL","501 FIFTH STREET","37620","000000","","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","Extracted from a download of OSHA's Enforcment Data downloaded on 3/02/2022, available at https://enforcedata.dol.gov/views/data_catalogs.php",""
"Wyeth LLC","Pfizer","$18,876,624","$0","$18,876,624","2012","20120807","competition-related offenses","Foreign Corrupt Practices Act","","","federal","agency action","Securities and Exchange Commission","civil","","","","","","","","","","","","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","https://www.sec.gov/News/PressRelease/Detail/PressRelease/1365171483696",""
"Wyeth Pharmaceuticals Inc.","Pfizer","$490,900,000","$0","$490,900,000","2013","20130730","healthcare-related offenses","off-label or unapproved promotion of medical products","","Wyeth Pharmaceuticals Inc., a pharmaceutical company acquired by Pfizer, Inc. in 2009, has agreed to pay $490.9 million to resolve its criminal and civil liability arising from the unlawful marketing of the prescription drug Rapamune for uses not approved as safe and effective by the U.S. Food and Drug Administration.","federal","agency action","Food and Drug Administration referral to the Justice Department","civil and criminal","","","","","","","","","","","","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","http://www.justice.gov/opa/pr/wyeth-pharmaceuticals-agrees-pay-4909-million-marketing-prescription-drug-rapamune-unapproved",""
"Wyeth Biopharma","Pfizer","$40,187","$0","$40,187","2005","20050630","employment-related offenses","wage and hour violation","Fair Labor Standards Act","","federal","agency action","Labor Department Wage and Hour Division","civil","","","1367427","","","Massachusetts","Andover","","01810","32541","32541: Pharmaceutical and Medicine Manufacturing","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","March 7, 2017 download of a dataset posted by the Wage and Hour Division at https://enforcedata.dol.gov/views/data_summary.php","Date and year are the Findings End Date in the dataset posted by the Wage and Hour Division, which does not provide case opening or closing dates. The company name is the Legal Name provided by the dataset unless that field is blank, in which case the Trade Name is used. The dataset provides only one address and does not indicate whether it is the company headquarters address or the establishment address. The penalty amount is the total of civil monetary penalties and mandated back wages. The original dataset provides a breakdown."
"Pfizer, Inc.","Pfizer","$23,850,000","$0","$23,850,000","2018","20180524","government-contracting-related offenses","False Claims Act and related","kickbacks and bribery","","federal","agency action","Justice Department Civil Division","civil","","","","","","","","","","","","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","https://www.justice.gov/opa/pr/drug-maker-pfizer-agrees-pay-2385-million-resolve-false-claims-act-liability-paying-kickbacks",""
"Pfizer","Pfizer","$1,365,003","$0","$1,365,003","2009","20091230","employment-related offenses","employment discrimination","Family and Medical Leave Act","","federal","private litigation","","civil","","Eastern District of North Carolina","5:04-cv-722","Dotson v. Pfizer, Inc.","verdict","","","","","","","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","https://caselaw.findlaw.com/us-4th-circuit/1159294.html",""
"Wyeth","Pfizer","$2,000,000","$0","$2,000,000","2013","20130521","employment-related offenses","benefit plan administrator violation","pension ERISA violation","","federal","private litigation","","civil","","Southern District of New York","1:08-cv-4688","Herrera v. Wyeth et al","settlement","","","","","","","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","https://www.law360.com/articles/404532",""
"Alpharma Inc.","Pfizer","$8,900,000","$8,900,000","$0","2010","20100316","government-contracting-related offenses","False Claims Act and related","kickbacks and bribery","Alpharma Inc. agreed to pay $8.9 million to settle multistate litigation alleging that it paid health care providers to induce them to promote or prescribe Kadian and made misrepresentations about the safety and efficacy of the drug. This was part of a larger $42.5 million settlement involving the federal government; see the Violation Tracker entry at https://violationtracker.goodjobsfirst.org/violation-tracker/-alpharma-inc","state","agency action","Multistate Attorneys General Case","civil","","","","","","","","","","","","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","https://www.justice.gov/opa/pr/alpharma-pay-425-million-resolve-false-claims-act-allegations-connection-promotion-drug",""
"Alpharma USPD, Inc.","Pfizer","$600,000","$0","$600,000","2010","20100527","government-contracting-related offenses","False Claims Act and related","","Alpharma USPD, Inc. and Purepac Pharmaceutical Co. agreed to pay a total of $1.2 million in settlement of allegations they misreported the average wholesale price of their drugs to the state Medicaid program. The announcement did not specify how much each company would pay; here we assume the total was split evenly between them.","state","agency action","Idaho Attorney General","civil","","","","","","Idaho","","","","","","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","https://web.archive.org/web/20110306105140/http://www.ag.idaho.gov/media/newsReleases/2010/nr_05272010.html",""
"Alpharma USPD, Inc. and Purepac Pharmaceutical Co.","Pfizer","$10,200,000","$0","$10,200,000","2011","20110330","government-contracting-related offenses","False Claims Act and related","","Alpharma USPD, Inc. and Purepac Pharmaceutical Co., subsidiaries of Actavis, agreed to pay $10.2 million in settlement of alleged improper reporting of the average wholesale price of their drugs, causing Medicaid to overpay.","state","agency action","Kentucky Attorney General","civil","","","","","","Kentucky","","","","","","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","https://web.archive.org/web/20150321231425/http://migration.kentucky.gov/Newsroom/ag/alpharmapurepacsettlement.htm",""
"Alpharma USPD, Inc.,","Pfizer","$2,010,667","$0","$2,010,667","2011","20111024","government-contracting-related offenses","False Claims Act and related","","Three companies agreed to pay a total of $6.032 million to settle litigation relating to the misreporting of wholesale drug prices, thus increased prices for the state's Medicaid program. The announcement did not indicate how much each would pay. Here we assume the total was divided equally among the three.","state","agency action","Mississippi Attorney General","civil","","","","","","Mississippi","","","","","","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","https://web.archive.org/web/20111026042046/http://www.ago.state.ms.us:80/index.php/press/releases/ag_reaches_additional_62_million_settlements_in_awp_cases/",""
"Alpharma, Inc.","Pfizer","$750,000","$0","$750,000","2004","20040812","competition-related offenses","price-fixing or anti-competitive practices","","Generic drug manufacturers Alpharma Inc. and Perrigo Company agreed to pay a total of $1.5 million to settle multistate litigation alleging they illegally limited competition for over-the-counter store-brand children's liquid ibuprofen and drove up prices. The announcement did not specify how much each company would pay. Here we assume they split the amount equally.","state","agency action","Multistate Attorneys General Case","civil","","","","","","","","","","","","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","https://www.ftc.gov/news-events/press-releases/2004/08/generic-drug-marketers-settle-ftc-charges",""
"King Pharmaceuticals","Pfizer","$124,000,000","$124,000,000","$0","2006","20060323","government-contracting-related offenses","False Claims Act and related","","King Pharmaceuticals agreed to pay $124 million to settle multistate litigation alleging that it failed to accurately report its average manufacturer price and its best price for certain pharmaceutical products. As a result, King underpaid Medicaid and other programs amounts that were due under the federal and state Medicaid Rebate Programs, which are designed to ensure that Medicaid receives the benefit of discounts that King made available to its commercial customers. The U.S. Department of Justice was also involved in the settlement and issued its own announcement; see the Violation Tracker entry at https://violationtracker.goodjobsfirst.org/violation-tracker/-king-pharmaceuticals","state","agency action","Multistate Attorneys General Case","civil","","","","","","","","","","","","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","https://web.archive.org/web/20100214182351/http://www.ag.ny.gov/media_center/2006/mar/mar23d_06.html",""
"Pfizer","Pfizer","$6,000,000","$0","$6,000,000","2003","20030106","safety-related offenses","drug or medical equipment safety violation","","Pfizer agreed to pay $6 million (including $2 million for a public service announcement campaign) to settle multistate litigation concerning its failure to include information about antibiotic resistance and other matters when marketing its Zithromax product to treat children's ear infections.","state","agency action","Multistate Attorneys General Case","civil","","","","","","","","","","","","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","https://www.oag.ca.gov/news/press-releases/attorney-general-lockyer-announces-settlement-pfizer-misrepresenting-drugs",""
"Pfizer","Pfizer","$35,000,000","$0","$35,000,000","2014","20140806","healthcare-related offenses","off-label or unapproved promotion of medical products","","Pfizer agreed to pay $35 million as part of the settlement of multistate litigation alleging improper marketing and promotion of the immunosuppressive drug Rapamune. ","state","agency action","Multistate Attorneys General Case","civil","","","","","","","","","","","","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","https://web.archive.org/web/20161130121010/http://ag.ny.gov/press-release/ag-schneiderman-announces-settlement-pfizer-end-deceptive-advertising-practices-and/",""
"Pfizer","Pfizer","$975,000","$0","$975,000","2019","20190311","consumer-protection-related offenses","consumer protection violation","","distribution of misleading marketing material and coupons","state","agency action","Oregon Attorney General","civil","","","","","","Oregon","","","","","","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","https://www.doj.state.or.us/media-home/news-media-releases/ag-rosenblum-announces-large-settlement-with-pfizer-for-misleading-drug-pricing-coupons/",""
"Pfizer Inc.","Pfizer","$21,084,700","$21,084,700","$0","2002","20021028","government-contracting-related offenses","False Claims Act and related","","Pfizer agreed to pay $21 million to settle multistate litigation alleging it violated the False Claims Act by failing to fully pay the rebates owed to state governments for the cholesterol-lowering drug Lipitor. This was part of a larger $49 million settlement involving the federal government; see the Violation Tracker entry at https://violationtracker.goodjobsfirst.org/violation-tracker/-pfizer-corporation","state","agency action","Multistate Attorneys General Case","civil","","","","","","","","","","","","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","https://www.justice.gov/archive/opa/pr/2002/October/02_civ_622.htm",""
"Pfizer Inc.","Pfizer","$2,621,154","$2,621,154","$0","2011","20111021","government-contracting-related offenses","False Claims Act and related","off-label or unapproved promotion of medical products","Pfizer agreed to pay $2.6 million to settle multistate litigation alleging that it marketed its drug Detrol for uses not approved by the Food and Drug Administration and thus caused false claims to be submitted to state Medicaid programs. This was part of a larger $14.5 million settlement involving the federal government; see the Violation Tracker entry at https://violationtracker.goodjobsfirst.org/violation-tracker/-pfizer-inc-0","state","agency action","Multistate Attorneys General Case","civil","","","","","","","","","","","","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","https://www.justice.gov/opa/pr/pfizer-pay-145-million-illegal-marketing-drug-detrol",""
"Pfizer Inc.","Pfizer","$60,000,000","$0","$60,000,000","2008","20081022","healthcare-related offenses","off-label or unapproved promotion of medical products","consumer protection violation","Pfizer agreed to pay $60 million to settle multistate litigation alleging that it engaged in unfair and deceptive practices in marketing its second-generation pain reliever, Bextra, for unapproved off-label uses.","state","agency action","Multistate Attorneys General Case","civil","","","","","","","","","","","","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","http://www.illinoisattorneygeneral.gov/pressroom/2008_10/20081022.html",""
"Pfizer Inc.","Pfizer","$375,000","$0","$375,000","2013","20131107","healthcare-related offenses","off-label or unapproved promotion of medical products","false advertising","Pfizer and Mylan agreed to pay a total of $625,000 in settlement of charges they ran a deceptive advertisement overstating the effectiveness of EpiPen.","state","agency action","Massachusetts Attorney General","civil","","","","","","Massachusetts","","","","","","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","https://web.archive.org/web/20131210003236/http://www.mass.gov/ago/news-and-updates/press-releases/2013/2013-11-07-epipen-ad-settlement.html",""
"Pfizer Inc.","Pfizer","$18,170,000","$0","$18,170,000","2013","20130104","government-contracting-related offenses","False Claims Act and related","","Falsification of wholesale drug price reporting. Federal government shared in the settlement. Penalty amount listed here is state portion only.","state","agency action","Texas Attorney General","civil","","","","","","Texas","","","","","","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","Attorney General Abbott Recovers $36.34 Million for State of Texas, U.S., Targeted News Service, January 4, 2013 (via Nexis).",""
"Pfizer Inc. and Pharmacia Corp.","Pfizer","$2,900,000","$0","$2,900,000","2012","20121227","government-contracting-related offenses","False Claims Act and related","","Pfizer Inc. and Pharmacia Corp. agreed to pay a total of $2.9 million in settlement of allegations they misreported the average wholesale price of their drugs.","state","agency action","Idaho Attorney General","civil","","","","","","Idaho","","","","","","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","https://web.archive.org/web/20140909020735/http://www.ag.idaho.gov/media/newsReleases/2012/nr_12272012.html",""
"Pfizer Inc.","Pfizer","$42,900,000","$0","$42,900,000","2012","20121212","healthcare-related offenses","off-label or unapproved promotion of medical products","consumer protection violation","Pfizer agreed to pay $42.9 million to settle multistate litigation alleging that it engaged in unlawful marketing of its drugs Zyvox and Lyrica, including the promotion of Lyrica for uses not approved by the Food and Drug Administration.","state","agency action","Multistate Attorneys General Case","civil","","","","","","","","","","","","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","https://www.atg.wa.gov/news/news-releases/washington-state-receives-13-million-settlement-pfizer",""
"Pfizer Inc.","Pfizer","$700,000","$0","$700,000","2018","20181011","consumer-protection-related offenses","consumer protection violation","","Pfizer agreed to pay $700,000 as part of the settlement of an investigation of its business and advertising practices for its copayment coupon program. As part of the program, consumers were told that they would pay no more than $15 or $20, for example, for certain drugs but ended up spending far more at the pharmacy cash register. ","state","agency action","New York Attorney General","civil","","","","","","New York","","","","","","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","A.G. Underwood Announces Settlement With Pfizer for Deceptive Advertising in 'Pay No More Than' Drug Copayment Card Program, Targeted News Service, October 11, 2018 (via Nexis).",""
"Pfizer, Inc.","Pfizer","$331,485,170","$331,485,170","$0","2009","20090902","competition-related offenses","kickbacks and bribery","","Pfizer agreed to pay more than $331 million to settle multistate litigation alleging that it paid illegal kickbacks and conducted improper marketing campaigns for more than a dozen of its drugs. This was part of a larger $2.3 billion civil and criminal settlement that also involved the federal government; see the Violation Tracker entry at https://violationtracker.goodjobsfirst.org/violation-tracker/-pfizer-inc-3","state","agency action","Multistate Attorneys General Case","civil","","","","","","","","","","","","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","https://www.justice.gov/opa/pr/justice-department-announces-largest-health-care-fraud-settlement-its-history",""
"Pfizer, Inc.","Pfizer","$3,340,000","$0","$3,340,000","2012","20120320","safety-related offenses","drug or medical equipment safety violation","","Pfizer agreed to pay the state $3.34 million to resolve allegations it made deceptive marketing claims related to its prescription drug Zyvox.","state","agency action","Oregon Attorney General","civil","","","","","","Oregon","","","","","","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","https://www.doj.state.or.us/media-home/news-media-releases/oregon-department-of-justice-reaches-landmark-3-34-million-agreement-with-pfizer/",""
"Pfizer, Inc. and Pharmacia Corporation","Pfizer","$8,200,000","$0","$8,200,000","2010","20101006","government-contracting-related offenses","False Claims Act and related","","Pfizer and its subsidiary Pharmacia agreed to pay $8.2 million as part of a series of settlements between pharmaceutical companies and Hawaii of allegations that they published inflated prices for drugs and thus increased Medicaid costs.","state","agency action","Hawaii Attorney General","civil","","","","","","Hawaii","","","","","","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","http://ag.hawaii.gov/wp-content/uploads/2012/12/2010-21.pdf",""
"Purepac Pharmaceutical Co.","Pfizer","$600,000","$0","$600,000","2010","20100527","government-contracting-related offenses","False Claims Act and related","","Alpharma USPD, Inc. and Purepac Pharmaceutical Co. agreed to pay a total of $1.2 million in settlement of allegations they misreported the average wholesale price of their drugs to the state Medicaid program. The announcement did not specify how much each company would pay; here we assume the total was split evenly between them.","state","agency action","Idaho Attorney General","civil","","","","","","Idaho","","","","","","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","https://web.archive.org/web/20110306105140/http://www.ag.idaho.gov/media/newsReleases/2010/nr_05272010.html",""
"Purepac Pharmaceutical Co., n/k/a Actavis Elizabeth, LLC","Pfizer","$2,010,667","$0","$2,010,667","2011","20111024","government-contracting-related offenses","False Claims Act and related","","Three companies agreed to pay a total of $6.032 million to settle litigation relating to the misreporting of wholesale drug prices, thus increased prices for the state's Medicaid program. The announcement did not indicate how much each would pay. Here we assume the total was divided equally among the three.","state","agency action","Mississippi Attorney General","civil","","","","","","Mississippi","","","","","","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","https://web.archive.org/web/20111026042046/http://www.ago.state.ms.us:80/index.php/press/releases/ag_reaches_additional_62_million_settlements_in_awp_cases/",""
"Warner-Lambert","Pfizer","$190,000,000","$190,000,000","$0","2004","20040513","healthcare-related offenses","off-label or unapproved promotion of medical products","","Warner-Lambert, a subsidiary of Pfizer, agreed to pay $190 million to resolve multistate litigation relating to the marketing of its drug Neurontin for uses not approved by the Food and Drug Administration. The total included $152 million to be paid to state Medicaid programs and $38 million to state consumer fraud offices. All this was part of a larger $430 million civil and criminal settlement also involving the federal government; see the Violation Tracker entry at https://violationtracker.goodjobsfirst.org/violation-tracker/-warner-lambert","state","agency action","Multistate Attorneys General Case","civil","","","","","","","","","","","","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","https://web.archive.org/web/20100214194003/http://www.ag.ny.gov/media_center/2004/may/may13b_04.html",""
"Wyeth Pharmaceuticals, Inc.","Pfizer","$371,351,180","$371,351,180","$0","2016","20160427","government-contracting-related offenses","False Claims Act and related","","Wyeth and its parent Pfizer agreed to pay $371 million to resolve multistate allegations that Wyeth knowingly reported to Medicaid agencies false and fraudulent prices on two of its proton pump inhibitor drugs, Protonix Oral and Protonix IV. This was part of a larger $784 million settlement involving the federal government; see the Violation Tracker entry at https://violationtracker.goodjobsfirst.org/violation-tracker/-pfizer-inc-2","state","agency action","Multistate Attorneys General Case","civil","","","","","","","","","","","","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","https://www.justice.gov/opa/pr/wyeth-and-pfizer-agree-pay-7846-million-resolve-lawsuit-alleging-wyeth-underpaid-drug-rebates",""
"Wyeth Pharmaceuticals, Inc.","Pfizer","$257,400,000","$257,400,000","$0","2013","20130730","healthcare-related offenses","off-label or unapproved promotion of medical products","","Wyeth agreed to pay $257.4 million to settle multistate litigation alleging that it promoted the sale and use of the kidney transplant drug Rapamune for uses not approved by the U.S. Food and Drug Administration. This was part of a larger $490.9 million civil and criminal settlement also involving the federal government, which issued its own announcement; see the Violation Tracker entry at https://violationtracker.goodjobsfirst.org/violation-tracker/-wyeth-pharmaceuticals-inc","state","agency action","Multistate Attorneys General Case","civil","","","","","","","","","","","","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","https://web.archive.org/web/20150906094937/http://www.ag.ny.gov/press-release/pharmaceutical-giant-pay-nearly-500-million-resolve-allegations-label-marketing-kidney",""
"Pfizer Inc.","Pfizer","$41,047,101","$0","$41,047,101","2019","20191028","government-contracting-related offenses","False Claims Act and related","","The Illinois Attorney General Kwame announced the recovery of $242 million in a settlement with numerous drug companies resolving allegations the companies inflated the wholesale prices used in setting the rates for Medicaid reimbursements.","state","agency action","Illinois Attorney General","civil","","","","","","","","","","","","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","http://www.illinoisattorneygeneral.gov/pressroom/2019_10/20191028.html",""
"Wyeth-Ayerst Laboratories Division","Pfizer","$30,000,000","$0","$30,000,000","2000","20001003","safety-related offenses","drug or medical equipment safety violation","","The Food and Drug Administration announced that Wyeth-Ayerst Laboratories Division of American Home Products Corporation and Wyeth- Ayerst Pharmaceuticals, Inc. signed a consent decree of permanent injunction in which Wyeth agreed to a series of measures aimed at ensuring that the products manufactured at Wyeth's Marietta, Pa. and Pearl River, N.Y. facilities are made in compliance with FDA's good manufacturing practice regulations.","federal","agency action","Food and Drug Administration","civil","","","","","","","","","","","","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","https://web.archive.org/web/20001219083500/http://www.fda.gov/bbs/topics/ANSWERS/ANS01041.html",""
"Pfizer Pharmaceuticals, LLC","Pfizer","$190,000","$0","$190,000","2016","20161025","environment-related offenses","environmental violation","","Clean Air Act","federal","agency action","Environmental Protection Agency referral to the Justice Department","civil","","","","","","Puerto Rico","Barceloneta","","","","","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","https://19january2017snapshot.epa.gov/newsreleases/epa-fines-pfizer-puerto-rico-not-disclosing-chemical-information_.html",""
"Pfizer Inc.","Pfizer","$9,500,000","$0","$9,500,000","2014","20141103","safety-related offenses","drug or medical equipment safety violation","","The Nevada Attorney General reached a $9.5 million settlement with Pfizer Inc. to resolve allegations that Pfizer and Wyeth Pharmaceuticals unlawfully promoted certain postmenopausal hormone therapy medications and misled Nevada consumers and physicians about the safety and efficacy of these drugs.","state","agency action","Nevada Attorney General","civil","","","","","","","","","","","","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","http://ag.nv.gov/News/PR/2014/Consumer_Protection/Attorney_General_Masto_Announces_an_$8_Million_Charitable_Contribution_as_Part_of_a_Settlement_with_Pfizer/",""
"Pfizer Inc.","Pfizer","$6,720","$0","$6,720","2012","20121001","environment-related offenses","environmental violation","","pesticide violation","state","agency action","California Department of Pesticide Regulation","civil","","","","","","California","","","","","","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","Contained in data obtained from the agency on October 6, 2020 in response to an open records request. ",""
"Pfizer, Inc.","Pfizer","$31,266","$0","$31,266","2010","20100929","environment-related offenses","environmental violation","","","state","agency action","Connecticut Department of Energy & Environmental Protection","civil","","","","","","Connecticut","Groton","","","","","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","https://www.ct.gov/deep/lib/deep/enforcement/consentorder/COAR2151.pdf","Captured from summaries produced by DEP; may not include full details of penalties."
"Pfizer Inc.","Pfizer","$40,224","$0","$40,224","2006","20060613","environment-related offenses","environmental violation","","","state","agency action","Connecticut Department of Energy & Environmental Protection","civil","","","","","","Connecticut","Groton","","","","","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","https://www.depdata.ct.gov/enforcement/createrpt.asp?Programopt=Air&Townopt=Andover&select=all&B1=Submit","Captured from summaries produced by DEP; may not include full details of penalties."
"Pfizer","Pfizer","$288,000,000","$0","$288,000,000","2013","20130228","safety-related offenses","drug or medical equipment safety violation","product safety violation","Pfizer disclosed that in 2012 it recorded a charge of $288 million to cover the cost of settling multi-district litigation alleging that its smoking cessation product Chantix was linked to depression and suicidal behavior.","federal","private litigation","","civil","","Northern District of Alabama","2:09cv2039","In re: Chantix (Varenicline) Products Liability Litigation","settlement","","","","","","","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","https://www.sec.gov/Archives/edgar/data/78003/000007800313000006/pfe-12312012xex13.htm",""
"Pfizer","Pfizer","$745,000,000","$0","$745,000,000","2008","20081017","safety-related offenses","drug or medical equipment safety violation","product safety violation","In October 2008 Pfizer said it was taking a charge of $894 million to cover litigation costs relating to its anti-inflammatory drugs Bextra and Celebrex. Of the total, $745 million was to cover product liability suits relating to the two drugs.","federal","private litigation","","civil","","Northern District of California","3:05md1699","In Re Bextra And Celebrex Marketing, Sales Practices And Products Liability","settlement","","","","","","","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","https://www.nytimes.com/2008/10/18/business/18drug.html",""
"Pfizer","Pfizer","$750,000,000","$0","$750,000,000","2004","20040122","safety-related offenses","drug or medical equipment safety violation","product safety violation","In January 2004 Pfizer announced that it had taken a $975 million charge to cover legal costs, including 35,000 personal injury lawsuits alleging that the diabetes drug Rezulin, which had been sold by its subsidiary Warner-Lambert, caused liver damage. The company did not announce the cost of the Rezulin settements, but it was reported that the amount was $750 million: https://pink.pharmaintelligence.informa.com/PS050916/Pfizer-settles-Rezulin-product-liability-litigation","federal","private litigation","","civil","","Southern District of New York","1:00cv2843","In Re: Rezulin Products Liability Litigation","settlement","","","","","","","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","https://www.sec.gov/Archives/edgar/data/78003/000089109204000229/e16658ex99.txt",""
"American Home Products","Pfizer","$3,750,000,000","$0","$3,750,000,000","2002","20020103","safety-related offenses","drug or medical equipment safety violation","product safety violation","In January 2002 American Home Products announced that it had finalized a $3.75 billion settlement of multi-district litigation concerning alleged harms caused by its diet drug combination known as fen-phen: https://www.sec.gov/Archives/edgar/data/5187/000000518702000005/ann10k01.txt.","federal","private litigation","","civil","","Eastern District of Pennsylvania","MDL No. 1203","IN RE: Diet Drugs (Phentermine/Fenfluramine/Dexfenfluramine) Products Liability Litigation","settlement","","","","","","","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","https://www.nytimes.com/2002/01/11/business/fen-phen-settlement-approved.html",""
"PFIZER, INC.","Pfizer","$9,600","$0","$9,600","2012","20120118","safety-related offenses","workplace safety or health violation","","","federal","agency action","Occupational Safety & Health Administration","civil","","","","","","Connecticut","GROTON","558 EASTERN POINT ROAD","06340","325412","325412: Pharmaceutical Preparation Manufacturing","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","Extracted from a download of OSHA's Enforcment Data downloaded on 3/02/2022, available at https://enforcedata.dol.gov/views/data_catalogs.php",""
"PFIZER INC / GROTON SITE","Pfizer","$22,500","$0","$22,500","2005","20050111","environment-related offenses","environmental violation","","","federal","agency action","Environmental Protection Agency","civil","","","01-2005-3001","","","","","","","","","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","Extracted from a download of the EPA's Enforcement and Compliance History Online (ECHO) ICIS FE&C file downloaded on 3/02/2022, available at http://echo.epa.gov/tools/data-downloads#downloads",""
"PFIZER GLOBAL MANUFACTURING","Pfizer","$975,000","$975,000","$0","2008","20080721","environment-related offenses","environmental violation","","","federal","agency action","Environmental Protection Agency","civil","","","01-2007-1206","","","","","","","","","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","Extracted from a download of the EPA's Enforcement and Compliance History Online (ECHO) ICIS FE&C file downloaded on 3/02/2022, available at http://echo.epa.gov/tools/data-downloads#downloads","Note: This penalty is a duplicate of an amount shown in another record (either because it applies to a multi-location settlement or because Violation Tracker contains an agency record and a settlement announcement for the same case)."
"WYETH PHARMACEUTICALS COMPANY - OTC","Pfizer","$25,000","$0","$25,000","2000","20000925","environment-related offenses","environmental violation","","","federal","agency action","Environmental Protection Agency","civil","","","02-2000-3314","","","Puerto Rico","GUAYAMA","CARR 3 KM 142.1","784","325412","325412: Pharmaceutical Preparation Manufacturing","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","Extracted from a download of the EPA's Enforcement and Compliance History Online (ECHO) ICIS FE&C file downloaded on 3/02/2022, available at http://echo.epa.gov/tools/data-downloads#downloads",""
"SEARLE LTD","Pfizer","$95,000","$0","$95,000","2002","20020313","environment-related offenses","environmental violation","","","federal","agency action","Environmental Protection Agency","civil","","","02-2002-7102","","","","","","","","","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","Extracted from a download of the EPA's Enforcement and Compliance History Online (ECHO) ICIS FE&C file downloaded on 3/02/2022, available at http://echo.epa.gov/tools/data-downloads#downloads",""
"Pfizer Pharmaceuticals Ltd.","Pfizer","$20,025","$0","$20,025","2004","20040127","environment-related offenses","environmental violation","","","federal","agency action","Environmental Protection Agency","civil","","","02-2003-3315","","","","","","","","","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","Extracted from a download of the EPA's Enforcement and Compliance History Online (ECHO) ICIS FE&C file downloaded on 3/02/2022, available at http://echo.epa.gov/tools/data-downloads#downloads",""
"Wyeth Ayerst Pharmaceuticals","Pfizer","$37,000","$0","$37,000","2004","20040224","environment-related offenses","environmental violation","","","federal","agency action","Environmental Protection Agency","civil","","","02-2003-7107","","","","","","","","","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","Extracted from a download of the EPA's Enforcement and Compliance History Online (ECHO) ICIS FE&C file downloaded on 3/02/2022, available at http://echo.epa.gov/tools/data-downloads#downloads",""
"Pfizer Pharmaceuticals LLC","Pfizer","$55,000","$0","$55,000","2005","20050706","environment-related offenses","environmental violation","","","federal","agency action","Environmental Protection Agency","civil","","","02-2005-7108","","","Puerto Rico","ARECIBO","PR-2 KM 60.0","612","325412","325412: Pharmaceutical Preparation Manufacturing","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","Extracted from a download of the EPA's Enforcement and Compliance History Online (ECHO) ICIS FE&C file downloaded on 3/02/2022, available at http://echo.epa.gov/tools/data-downloads#downloads",""
"Wyeth Rouses Point","Pfizer","$44,500","$0","$44,500","2008","20080926","environment-related offenses","environmental violation","","","federal","agency action","Environmental Protection Agency","civil","","","02-2007-3342","","","","","","","","","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","Extracted from a download of the EPA's Enforcement and Compliance History Online (ECHO) ICIS FE&C file downloaded on 3/02/2022, available at http://echo.epa.gov/tools/data-downloads#downloads",""
"Wyeth Pharmaceuticals Company, Inc.","Pfizer","$77,000","$0","$77,000","2010","20100318","environment-related offenses","environmental violation","","","federal","agency action","Environmental Protection Agency","civil","","","02-2009-3460","","","Puerto Rico","GUAYAMA","STATE ROAD NO 3, KM 142.1","655","325412","325412: Pharmaceutical Preparation Manufacturing","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","Extracted from a download of the EPA's Enforcement and Compliance History Online (ECHO) ICIS FE&C file downloaded on 3/02/2022, available at http://echo.epa.gov/tools/data-downloads#downloads",""
"Pfizer Pharmaceuticals","Pfizer","$24,650","$0","$24,650","2010","20100727","environment-related offenses","environmental violation","","","federal","agency action","Environmental Protection Agency","civil","","","02-2010-9302","","","Puerto Rico","BARCELONETA","KM 58.2 RTE 2","617","325412","325412: Pharmaceutical Preparation Manufacturing","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","Extracted from a download of the EPA's Enforcement and Compliance History Online (ECHO) ICIS FE&C file downloaded on 3/02/2022, available at http://echo.epa.gov/tools/data-downloads#downloads",""
"Pfizer Pharmaceuticals, LLC","Pfizer","$728,000","$728,000","$0","2014","20140508","environment-related offenses","environmental violation","","","federal","agency action","Environmental Protection Agency","civil","","","02-2012-1220","","","","","","","","","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","Extracted from a download of the EPA's Enforcement and Compliance History Online (ECHO) ICIS FE&C file downloaded on 3/02/2022, available at http://echo.epa.gov/tools/data-downloads#downloads","Note: This penalty is a duplicate of an amount shown in another record (either because it applies to a multi-location settlement or because Violation Tracker contains an agency record and a settlement announcement for the same case)."
"KING PHARMACEUTICALS","Pfizer","$2,200,000","$2,200,000","$0","2013","20130822","environment-related offenses","environmental violation","","","federal","agency action","Environmental Protection Agency","civil","","","04-2006-9147","","","Tennessee","BRISTOL","501 FIFTH ST","37620","325412","325412: Pharmaceutical Preparation Manufacturing","USA","New York","publicly traded","PFE","pharmaceuticals","pharmaceuticals","Extracted from a download of the EPA's Enforcement and Compliance History Online (ECHO) ICIS FE&C file downloaded on 3/02/2022, available at http://echo.epa.gov/tools/data-downloads#downloads","Note: This penalty is a duplicate of an amount shown in another record (either because it applies to a multi-location settlement or because Violation Tracker contains an agency record and a settlement announcement for the same case)."
